BRCA1 and breast carcinoma: A successful example of this concept is the approval of poly(ADP)ribose polymerase (PARP) inhibitors (PARPi) to target BRCA1/2-deficient ovarian and breast cancers (20, 21), with relatively moderate side effects [reviewed in (22, 23)].